Glaukos Price to Book Ratio 2014-2022 | GKOS
Historical price to book ratio values for Glaukos (GKOS) over the last 10 years. The current price to book ratio for Glaukos as of January 27, 2023 is 4.16.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Glaukos Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-01-27 |
48.04 |
|
4.17 |
| 2022-09-30 |
53.24 |
$11.51 |
4.63 |
| 2022-06-30 |
45.42 |
$11.86 |
3.83 |
| 2022-03-31 |
57.82 |
$12.69 |
4.56 |
| 2021-12-31 |
44.44 |
$12.50 |
3.55 |
| 2021-09-30 |
48.17 |
$12.83 |
3.76 |
| 2021-06-30 |
84.83 |
$12.57 |
6.75 |
| 2021-03-31 |
83.93 |
$12.82 |
6.54 |
| 2020-12-31 |
75.26 |
$14.75 |
5.10 |
| 2020-09-30 |
49.52 |
$14.76 |
3.36 |
| 2020-06-30 |
38.42 |
$14.87 |
2.58 |
| 2020-03-31 |
30.86 |
$14.54 |
2.12 |
| 2019-12-31 |
54.47 |
$15.48 |
3.52 |
| 2019-09-30 |
62.51 |
$5.15 |
12.14 |
| 2019-06-30 |
75.40 |
$5.13 |
14.71 |
| 2019-03-31 |
78.37 |
$5.11 |
15.35 |
| 2018-12-31 |
56.17 |
$4.82 |
11.67 |
| 2018-09-30 |
64.90 |
$4.54 |
14.29 |
| 2018-06-30 |
40.64 |
$4.23 |
9.61 |
| 2018-03-31 |
30.83 |
$4.11 |
7.51 |
| 2017-12-31 |
25.65 |
$3.99 |
6.43 |
| 2017-09-30 |
33.00 |
$3.82 |
8.63 |
| 2017-06-30 |
41.47 |
$3.66 |
11.34 |
| 2017-03-31 |
51.30 |
$3.59 |
14.30 |
| 2016-12-31 |
34.30 |
$3.46 |
9.93 |
| 2016-09-30 |
37.74 |
$3.31 |
11.41 |
| 2016-06-30 |
29.16 |
$3.19 |
9.13 |
| 2016-03-31 |
16.86 |
$3.03 |
5.57 |
| 2015-12-31 |
24.69 |
$2.96 |
8.35 |
| 2015-09-30 |
24.19 |
$2.95 |
8.19 |
| 2015-06-30 |
28.98 |
$2.97 |
9.77 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$2.298B |
$0.294B |
|
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
|
